Duncan NRI Faculty and Staff Publications

Language

English

Publication Date

10-26-2023

Journal

Nature Communications

DOI

10.1038/s41467-023-42252-z

PMID

37884512

PMCID

PMC10603104

PubMedCentral® Posted Date

10-26-2023

PubMedCentral® Full Text Version

Post-print

Abstract

Technologies capable of programmable translation activation offer strategies to develop therapeutics for diseases caused by insufficient gene expression. Here, we present "translation-activating RNAs" (taRNAs), a bifunctional RNA-based molecular technology that binds to a specific mRNA of interest and directly upregulates its translation. taRNAs are constructed from a variety of viral or mammalian RNA internal ribosome entry sites (IRESs) and upregulate translation for a suite of target mRNAs. We minimize the taRNA scaffold to 94 nucleotides, identify two translation initiation factor proteins responsible for taRNA activity, and validate the technology by amplifying SYNGAP1 expression, a haploinsufficiency disease target, in patient-derived cells. Finally, taRNAs are suitable for delivery as RNA molecules by lipid nanoparticles (LNPs) to cell lines, primary neurons, and mouse liver in vivo. taRNAs provide a general and compact nucleic acid-based technology to upregulate protein production from endogenous mRNAs, and may open up possibilities for therapeutic RNA research.

Keywords

Animals, Mice, Humans, Protein Biosynthesis, Up-Regulation, Gene Expression Regulation, RNA, Messenger, Internal Ribosome Entry Sites, Mammals, Synthetic biology, RNA, Translation, Ribosome, Gene regulation

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.